Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if acetyl-L-carnitine (ALC) reduces pain, numbness,
and tingling in the feet and legs of patients with nucleoside reverse transcriptase inhibitor
(NRTI)-associated peripheral neuropathy. Another purpose is to determine if ALC is safe and
tolerable in HIV patients who have taken certain anti-HIV drugs.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)